Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11904614 | 0.86 | TSHR (0.47) | TSHRMAPTKMT2APAX8LMNA | |
| SCHEMBL2063413 | 0.83 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL11904297 | 0.83 | TSHR (0.45) | TSHRMAPTKMT2APAX8LMNA | |
| SCHEMBL312318 | 0.82 | HDAC8 (0.42) | TSHRMAPTKMT2ALMNATAS1R3 | |
| Hydrochloric Acid SCHEMBL311436 | 0.82 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL16464797 | 0.79 | STAT3 (0.46) | TSHRMAPTKMT2APAX8LMNA | |
| SCHEMBL3695054 | 0.74 | RECQL (0.60) | TSHRMAPTKMT2ALMNACYP1A2 | |
| SCHEMBL3189180 | 0.73 | ERAP1 (0.46) | MAPTLMNA | |
| SCHEMBL31073539 | 0.72 | HPGD (0.50) | TSHRMAPTKMT2ATAS1R3TAS1R1 | |
| SCHEMBL2074095 | 0.72 | TAS1R3 (0.49) | TSHRMAPTTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8334293-B2 | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy | ELI LILLY AND COMPANY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | MTOR, RPS6KA1, RPS6KA4 | TSHR 4173/4885MAPT 2656/4885KMT2A 646/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | TSHR 2367/4885MAPT 814/4885KMT2A 3302/4885 |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | RPS6KA1, RPS6KA3, RPS6KA4 | TSHR 3509/4885MAPT 2516/4885KMT2A 857/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | TSHR 2367/4885MAPT 814/4885KMT2A 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.